Royal Pharma
Royal Pharma, officially known as Royal Pharmaceuticals, is a prominent player in the pharmaceutical industry, headquartered in India. Established in 2005, the company has made significant strides in the development and distribution of high-quality generic and specialty medications, primarily serving the Indian market and expanding its reach across various international regions. With a focus on therapeutic areas such as oncology, cardiology, and neurology, Royal Pharma distinguishes itself through its commitment to innovation and rigorous quality standards. The company’s core offerings include a diverse range of formulations that cater to both chronic and acute health conditions, ensuring accessibility and affordability for patients. Recognised for its robust research and development capabilities, Royal Pharma has achieved notable milestones, positioning itself as a trusted name in the pharmaceutical sector. Its dedication to excellence and patient-centric approach continues to drive its growth and reputation in the industry.
DitchCarbon Score
How does Royal Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Royal Pharma's score of 14 is lower than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Royal Pharma's reported carbon emissions
Royal Pharma currently does not have available carbon emissions data, as indicated by the absence of specific figures for kg CO2e. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. As such, Royal Pharma's climate commitments and strategies remain unspecified, and there is no inherited emissions data from a parent or related organization. Without concrete data or targets, it is challenging to assess their environmental impact or commitment to sustainability within the pharmaceutical industry.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Royal Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
